GlassScriptPhysician profile
Martha S Housholder
NPI 1508848144
$4,849.29
in general payments reported to CMS, 2019-2025
30 companies · $913 in 2025
The $913 reported for 2025 was more than what a typical Dermatopathology (Dermatology) provider received nationally (typical 2025 total: $251).
See the full distribution for Dermatopathology (Dermatology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $546 · 2020: $243 · 2021: $648 · 2022: $869 · 2023: $904 · 2024: $726 · 2025: $913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,472 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,471.67 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,091.06 | 2019-2025 | |
| Amgen INC. | $655.48 | 2020-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $590.70 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Novartis Pharmaceuticals Corporation | $554.90 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $422.30 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $381.69 | 2021-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $265.65 | 2019-2025 | Blu-U |
| Regeneron Healthcare Solutions, INC. | $96.62 | 2022-2025 | Dupixent, Libtayo |
| Dermavant Sciences, INC. | $93.32 | 2022-2023 | Vtama |
| Sanofi-Aventis U.S. LLC | $72.00 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $70.75 | 2019 | |
| Arcutis Biotherapeutics, INC. | $65.91 | 2024-2025 | Zoryve |
| Genzyme Corporation | $62.58 | 2019-2024 | |
| Pfizer INC. | $58.74 | 2021-2023 | |
| Genentech USA, INC. | $50.56 | 2019-2023 | Erivedge |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $42.28 | 2021-2022 | |
| Fresenius Kabi USA, LLC | $40.80 | 2023 | Idacio |
| Merck Sharp & Dohme LLC | $36.47 | 2019 | |
| Ucb, INC. | $28.29 | 2025 | Bimzelx |
| Kerecis Limited | $20.49 | 2022 | |
| Lilly USA, LLC | $18.58 | 2024 | Taltz |
| Kyowa Kirin, INC. | $18.29 | 2023 | Poteligeo |
| Vyne Pharmaceuticals INC. | $18.09 | 2020 | |
| Alnylam Pharmaceuticals INC. | $16.19 | 2024 | Givlaari |
| Journey Medical Corporation | $14.17 | 2021 | |
| Paratek Pharmaceuticals, INC. | $13.98 | 2023 | Nuzyra |
| Galderma Laboratories, L.P. | $13.34 | 2024 | |
| Biofrontera INC. | $12.86 | 2019 | |
| Sandoz INC. | $12.40 | 2020 | |
| Reprise Biomedical, INC. | $10.80 | 2025 | Miro3d |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martha Housholder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.